Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Ewing Sarcoma
Drug:
temozolomide
(
DNA synthesis inhibitor
) +
irinotecan
(
Topoisomerase I inhibitor
) +
vincristine
(
Tubulin polymerization inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
11/20/2020
Excerpt:
Ewing sarcoma: Second-line therapy (relapsed/refractory or metastatic disease)…Preferred Regimens…Irinotecan + Temozolomide ± vincristine
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.